ReviewEMBO molecular medicine2015
Lost in translation: pluripotent stem cell-derived hematopoiesis.
Review in EMBO molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 98 citations in OpenAlex.
- Opportunities and challenges for cancer immunotherapy based on antigen cross-presentation.Annals of medicine · 2026Review
- Regulatory T cell therapies: biological foundations, engineering strategies, and clinical translation.Frontiers in immunology · 2026Review
- Chimeric brain models: Unlocking insights into human neural development, aging, diseases, and cell therapies.Neuron · 2025Review
- Hematopoietic stem cells and HSCs-derived from pluripotent stem cells: a hopeful outlook in cell-based therapeutics.Molecular biology reports · 2025Review
- Antifragile Treatment for Efficient Chimerism of Induced Pluripotent Stem Cells Derived Hematopoietic Stem Cells.Stem cell reviews and reports · 2025Article
- In vitro erythropoiesis: the emerging potential of induced pluripotent stem cells (iPSCs).Blood science (Baltimore, Md.) · 2025Review
- Unlocking the Potential of Induced Pluripotent Stem Cells in Revolutionizing Cancer Therapy.Current stem cell research & therapy · 2025Review
- Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.Stem cell reports · 2024Article
- Comparison of osteoclast differentiation protocols from human induced pluripotent stem cells of different tissue origins.Stem cell research & therapy · 2023Article
- Comparison of osteoclast differentiation protocols from human induced pluripotent stem cells of different tissue origins.Research square · 2023Article
- Susceptibilities of CNS Cells towards Rabies Virus Infection Is Linked to Cellular Innate Immune Responses.Viruses · 2022Article
- ABO gene editing for the conversion of blood type A to universal type O in RhClinical and translational medicine · 2022Article
- Review
- Review
- Cell Cluster Sorting in Automated Differentiation of Patient-specific Induced Pluripotent Stem Cells Towards Blood Cells.Frontiers in bioengineering and biotechnology · 2022Article
- Review
- Recapitulative haematopoietic development of human pluripotent stem cells in the absence of exogenous haematopoietic cytokines.Journal of cellular and molecular medicine · 2021Article
- A 3D iPSC-differentiation model identifies interleukin-3 as a regulator of early human hematopoietic specification.Haematologica · 2021Article
- Human DC3 Antigen Presenting Dendritic Cells From Induced Pluripotent Stem Cells.Frontiers in cell and developmental biology · 2021Article
- The Immune-Modulatory Properties of iPSC-Derived Antigen-Presenting Cells.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pluripotent stem cells (PSCs) such as embryonic stem cells or induced pluripotent stem cells represent a promising cell type to gain novel insights into human biology. Understanding the differentiation process of PSCs in vitro may allow for the identification of cell extrinsic/intrinsic factors, driving the specification process toward all cell types of the three germ layers, which may be similar to the human in vivo scenario. This would not only lay the ground for an improved understanding of human embryonic development but would also contribute toward the generation of novel cell types used in cell replacement therapies. In this line, especially the developmental process of mesodermal cells toward the hematopoietic lineage is of great interest. Therefore, this review highlights recent progress in the field of hematopoietic specification of pluripotent stem cell sources. In addition, we would like to shed light on emerging factors controlling primitive and definitive hematopoietic development and to highlight recent approaches to improve the differentiation potential of PSC sources toward hematopoietic stem/progenitor cells. While the generation of fully defined hematopoietic stem cells from PSCs remains challenging in vitro, we here underline the instructive role of cell extrinsic factors such as cytokines for the generation of PSC-derived mature hematopoietic cells. Thus, we have comprehensively examined the role of cytokines for the derivation of mature hematopoietic cell types such as macrophages, granulocytes, megakaryocytes, erythrocytes, dendritic cells, and cells of the B- and T-cell lineage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.